First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.
about
Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implicationsThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaWeight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.Schizophrenia endophenotypes as treatment targets.Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialWeight gain in antipsychotic-naive patients: a review and meta-analysis.Weight gain associated with taking psychotropic medication: an integrative review.Antipsychotic interventions in prodromal psychosis: safety issues.Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.Abuse of olanzapine by substance abusers.Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.Olanzapine abuse.
P2860
Q24644239-1906841F-D660-45B9-AD8B-258321CAC856Q33566124-B8B72D13-BF45-41CE-ACC0-BFC84FCCC6E2Q34418847-4A340BB3-76E1-4C09-AC7F-7DBD610ED214Q35186007-3546841F-CFD2-48CB-98A0-0185A7A4FA85Q36178681-C0CA4C44-ABC5-4335-B7A6-34F20DF366B5Q36183650-37742E1A-57B2-4D2E-954F-A381502E8A47Q36202865-58AC3E51-E8D2-4B8C-9CEC-39D33CA7BA85Q36936347-138EB2FF-CC21-43B3-89D5-704F1CCFFCC0Q37078993-D5F4BCF8-01B6-463E-AF25-BD5030D7A041Q37572952-9FAE0D84-5222-4CC3-9C7F-C2F1DF03F875Q37865068-A9AAFC54-F7AC-4C30-B476-03EFDF564CE4Q38084211-8BF9001C-3141-42E5-BE1E-B2CCA0A89E8AQ38403164-6B4E285B-CD5C-4FE3-A03C-908AE96B7D1FQ42608128-D508E480-F5E5-44B0-BB96-FADF02B7BEC9Q42688877-1A0233B4-4509-43AD-A172-3443DF1CDFB7Q46832986-FD083BC1-207C-4224-AE3C-75722FF3E7DDQ47262415-C4CBB558-0EC9-43B1-828D-DBF5A3301AF1Q48199978-3FE4AC68-8FBA-435B-BDAC-C7775CE0AE08
P2860
First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
First-episode schizophrenia: a ...... ent and safety considerations.
@ast
First-episode schizophrenia: a ...... ent and safety considerations.
@en
type
label
First-episode schizophrenia: a ...... ent and safety considerations.
@ast
First-episode schizophrenia: a ...... ent and safety considerations.
@en
prefLabel
First-episode schizophrenia: a ...... ent and safety considerations.
@ast
First-episode schizophrenia: a ...... ent and safety considerations.
@en
P2093
P1433
P1476
First-episode schizophrenia: a ...... ent and safety considerations.
@en
P2093
Deanna L Kelly
Robert R Conley
William T Carpenter
P304
P356
10.2165/00003495-200565080-00006
P577
2005-01-01T00:00:00Z
P6179
1050343149